The QualityStocks Daily Friday, May 3rd, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (EVLV) +66.39%

PoliticsAndMyPortfolio (RHE) +40.00%

StreetInsider (MERC) +23.67%

The QualityStocks Daily Stock List

Freddie Mac (FMCKL)

Penny Stock Tweets, 4-Traders, Interactive Brokers, OTC Markets, Pink Investing, stockcharting.tips, Wallmine, MarketWatch, Nasdaq, Stockhouse, moneyhub, GuruFocus, Investors Hangout, InvestorsHub, Trading View, Barchart, and Seeking Alpha reported earlier on Freddie Mac (FMCKL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Freddie Mac operates in the secondary mortgage market in the U.S. It buys residential mortgage loans originated by lenders, and also invests in mortgage loans and mortgage-related securities. Freddie Mac supports the housing market and the nation's renters, homebuyers and homeowners throughout the entire nation and in all economic cycles. The Company is headquartered in McLean, Virginia and was chartered by Congress in 1970.

Freddie Mac operates by way of three business lines. These comprise Single-Family, Multifamily, and Capital Markets. The Company's Single-Family business supports responsible, sustainable homeownership. Freddie Mac works with lenders of all sizes - national, regional, and community lenders and credit unions - to purchase conventional, conforming mortgage loans for one- to four-unit homes (including condominiums and manufactured homes) up to a certain dollar amount set by the Company's regulator.

Freddie Mac Multifamily (working with a network of specialized vendors) provides funding for loans on properties ranging from five units to hundreds of units across manifold buildings. Moreover, the Company's Capital Markets business promotes the mortgage market's liquidity. It makes funding more available to borrowers through buying mortgage-related securities guaranteed by Freddie Mac and other financial institutions as investments and managing its portfolio.

Because it operates in the U.S. secondary mortgage market, Freddie Mac doesn't lend directly to borrowers. The Company purchases loans that meet its standards from approved lenders. With the money that lenders receive in return, they can make loans to other qualified borrowers. In securitizing pools of mortgages and selling the securities to investors, Freddie Mac shifts a major portion of the credit risk associated with the loans it owns to private investors – away from taxpayers.

The Wall Street Journal reported recently that Freddie Mac is providing financing for a portfolio of over 300 rental homes under a now-defunct pilot program intended to help address the shortage of homes for middle-class families. The close to $26 million pact with Atlanta-based Promise Homes provides financing for these 300 affordable rental homes.

Freddie Mac (FMCKL), closed Friday's trading session at $9.37, up 0.75%, on 16,502 volume with 10 trades. The average volume for the last 3 months is 90,669 and the stock's 52-week low/high is $4.45/$9.37.

chart

AIT Therapeutics, Inc. (AITB)

NetworkNewsWire, Zacks, Trading View, Barchart, Stockhouse, Stockopedia, Investor Place, Insider Financial, Street Insider, last10k, Wallet Investor, GuruFocus, Wolfstreet, MarketWatch, Emerging Growth, Morningstar, Real Investment Advice, 4-Traders, and Tip Ranks reported previously on AIT Therapeutics, Inc. (AITB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AIT Therapeutics, Inc. is a clinical-stage medical device and biopharmaceutical company based in Garden City, New York. It focuses on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions. These include serious lung infections and pulmonary hypertension. AIT Therapeutics also has an office in Ness Ziona, Israel. The Company's shares trade on the OTC Markets' OTCQB and AIT has submitted an application to be up-listed on the NASDAQ stock exchange with potential approval and completion by the end of Q1 calendar 2019.

At present, AIT Therapeutics is applying its therapeutic expertise to treat lower respiratory tract infections not effectively addressed with current standards of care, and also pulmonary hypertension, in diverse settings. The Company is now advancing its pioneering NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections. This includes nontuberculous mycobacteria (NTM).

AIT's propriety generator and delivery system generates NO from room air. This eliminates the requirement for costly and cumbersome cylinders. The Company's system allows for numerous significant advantages over approved NO cylinder based systems now used in hospitals globally and may allow for use in the home setting.

NO is recognized as an important molecule involved in many physiological and pathological processes. NO is naturally produced by the body's immune system to provide a first line of defense against invading pathogens. NO is a powerful molecule and has a short half-life of a few seconds in the blood. This enables it to be cleared fast from the body.

AIT Therapeutics has a commercial licensing agreement with Circassia Pharmaceuticals for AIT's novel, cylinder free, ventilator compatible NO generator and phasic-flow delivery system (AirNOvent) in the U.S. and China for use in the hospital setting at NO concentrations <= 80 ppm. Circassia Pharmaceuticals is a respiratory-focused specialty pharmaceutical company.

This deal allows AIT Therapeutics to take advantage of Circassia's expertise and footprint in specialty hospitals and the nitric oxide market in preparation for a potential U.S. launch in the first half of calendar 2020. AIT has already received $10.5 million in milestones from Circassia Pharmaceuticals and is entitled to $22.05 million of future milestone payments and meaningful royalties on gross profits.

AIT Therapeutics, Inc. (AITB), closed Friday's trading session at $5.30, up 10.65%, on 61,694 volume with 143 trades. The average volume for the last 3 months is 18,696 and the stock's 52-week low/high is $2.23/$5.50.

chart

Precision Optics Corp., Inc. (PEYE)

MarketWatch, Stockhouse, Bull Trends, last10k, Morningstar, Investor Trendz, Penny Stock Scholar, OTCtipReporter, Small Cap Investor Daily, GuruFocus, Club Penny Stocks Network, Growing Stocks Reports, 4-Traders, Barchart, Research Driven Investor, Marketbeat, Pumps and Dumps, Michael Stone, Wallet Investor, and Infront Analytics reported previously on Precision Optics Corp., Inc. (PEYE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Precision Optics Corp., Inc., emoploying proprietary optical technologies, is a leading developer and manufacturer of advanced optical instruments. It designs and produces next generation medical instruments, Microprecision™ micro-optics with characteristic dimensions under 1 millimeter, and other advanced optical systems for a wide variety of customers. Precision Optics is based in Gardner, Massachusetts and lists on the OTC Markets' OTCQB.

Precision Optics has expertise in providing lenses to sizes as small as 0.2mm in diameter using its proprietary Microprecision™ technology with the quality of ground lenses approaching the cost of gradient index (GRIN) lenses. The Company's expertise includes the design, development, and manufacturing of optical and mechanical-optical components, sub-assemblies, and systems. These include lenses, prisms, thin film coatings, optical assemblies, sinuscopes, arthroscopes, laparoscopes, stereo-endoscopes, beamsplitters, endocouplers, camera adapters and fiber optic assemblies.

Precision Optics provides optical components, optical system design and production of different lens and prism products for the defense and aerospace industries. The Company's belief is that current advances in its proprietary micro-optics and 3D imaging technologies present major opportunities for expanding applications to numerous potential medical products and procedures.

Regarding Micro-Optics & Components, Precision Optics has an in-house optical shop, flexible manufacturing, and a staff of highly trained optical designers and technicians. The Company can manufacture cost-effectively in prototype, low or high volumes.

Recently, Precision Optics announced operating results on an unaudited basis for its fiscal year 2019 Q2 and six months ended December 31, 2018. The Company had Revenues of $1,478,000 in the quarter ended December 31, 2018 versus $813,000 in the same quarter of the prior year. This represents 82 percent growth.

It had Revenues of $3,037,000 in the six months ended December 31, 2018 versus $1,842,000 in the same six month period of the prior year. This represents 65 percent growth. Precision Optics had a 282 percent and 310 percent increase in production revenues in the quarter and six month periods ended December 31, 2018 versus the same periods of the prior year, and this drove Company-wide growth.

Precision Optics Corp., Inc. (PEYE), closed Friday's trading session at $1.45, up 3.57%, on 4,550 volume with 4 trades. The average volume for the last 3 months is 6,564 and the stock's 52-week low/high is $0.50/$1.85.

chart

Bion Environmental Technologies, Inc. (BNET)

TopPennyStockMovers, StockGuru, Marketbeat, 4-Traders, Proactive Investors, SECFilings.com News, OTC Stock Review, and Wall Street Resources reported earlier on Bion Environmental Technologies, Inc. (BNET), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Bion Environmental Technologies, Inc. is a developer of advanced livestock waste treatment and resource recovery technology. Its patented, next-generation technology provides verified comprehensive treatment of animal waste from large-scale livestock production facilities. Bion Environmental Technologies is headquartered in Crestone, Colorado. The Company's administrative office is in Old Bethpage, New York. Bion lists on the OTC Markets Group's OTCQB.

Bion's technology platform is a modular system. It can be configured in an array of ways, depending on farm- and region-specific needs. This system creates new revenue sources and opportunities for the producer. The Company's technology platform achieves substantial reductions in environmental impacts. This includes nutrients (nitrogen and phosphorus), ammonia, greenhouse and other gases, and pathogens in the waste stream. This is while improving resource and operational efficiencies via the recovery of valuable byproducts.

Bion's 2nd generation (2G) Comprehensive Environmental Management System removes up to 95 percent of the nutrients from the livestock waste effluent. It considerably decreases air emissions. This includes ammonia (as great as 90 percent or more), greenhouse gases, hydrogen sulfide, VOC's, and others. The system extracts renewable energy from the waste stream in the form of cellulosic biomass.

The Company's treatment solutions are a combination of biological, mechanical, as well as thermal processes. These are proven in commercial operations. They have been accepted by the EPA (Environmental Protection Agency), the USDA (United States Department of Agriculture), and other regulatory agencies.

Recently, Bion Environmental Technologies announced it filed an application under the Patent Cooperation Treaty (PCT) for international recognition of its process to produce a quick-release organic nitrogen fertilizer from livestock waste. The PCT application allows the Company to file patent applications and seek protection in most major market countries globally. The U.S. Patent and Trademark Office (USPTO) issued Patent No. 10,106,447 B2 on October 23, 2018, the first patent issued on Bion's third-generation technology.

Bion Environmental Technologies, Inc. (BNET), closed Friday's trading session at $0.80, up 4.59%, on 14,158 volume with 16 trades. The average volume for the last 3 months is 9,600 and the stock's 52-week low/high is $0.37/$0.80.

chart

Novo Resources Corp. (NSRPF)

Energy and Gold, The OTC Reporter, Spotlight Growth, MarketWatch, YCharts, Emerging Growth, Dividend Investor, Capital Cube, Investors Hangout, GuruFocus, Junior Mining Network, The Online Investor, OTC Markets, Insider Financial, Metals News, Streetwise Reports, 4-Traders, StockInvest, Mining Stock Valuator, Stockhouse, InvestorsHub, Finance Registrar, and Trading View reported on Novo Resources Corp. (NSRPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Novo Resources Corp.'s focus is to evaluate, acquire, as well as explore gold properties. Its current emphasis is to explore and develop gold projects in the Pilbara area of Western Australia. The Company has built up a considerable land package covering approximately 12,000 sq km. Novo Resources is based in Vancouver, British Columbia. The Company's shares trade on the OTC Markets' OTCQX.
 
Novo Resources also controls a 100 percent interest in approximately 2 sq kms encompassing much of the Tuscarora Au-Ag vein district in Nevada. The Company's current focus is its Beatons Creek and Marble Bar paleoplacer gold projects in Western Australia. Novo owns the roughly10 sq km Beatons Creek Tenements in Western Australia. Wide-ranging test work conducted on Beatons Creek conglomerates indicates high gravity recoveries.

The Company has the right to earn a 70 percent interest in the roughly 1,800 sq km Pilbara Paleoplacer Gold Project, which includes the Beatons Creek and Marble Bar paleoplacer gold projects, in Western Australia from the Creasy Group. In addition, Novo has acquired, via staking, a 100 percent interest in approximately 6,021 sq kms of mineral rights in the Karratha area. It staked exploration applications covering about 7,000 sq kms in the area around Karratha. The Company controls roughly an additional 2,000 sq kms elsewhere in the Pilbara region.

Regarding the Karratha Gold Project, Novo Resources entered into farm-in and joint venture (JV) agreements with Artemis Resources to earn-in on an additional 1,256 sq kms of mineral rights. Additionally, the Company entered into sale and purchase agreements and farm-in and JV agreements for an 80 percent interest in the Comet Well property. It also entered into an option agreement for 100 percent of Welcome Exploration's gold rights.

At the end of January, Novo Resources announced that it received encouraging results from initial testing of mechanical rock sorting of gold-bearing conglomerate from its Karratha gold project. The potential feasibility of mechanical rock sorting was tested by subjecting four bulk samples to crushing, screening, as well as sorting using a TOMRA mechanical rock sorter. Sorted rock concentrates of very small volume were generated returning high gold contents.

Recently, Novo Resources announced advancements in resource work including wireframe modeling and receipt of initial results from its bulk sampling program at its Beatons Creek project in Nullagine, WA. Final bulk sample assays are expected shortly. At that time, work on a new resource model will be completed. The Company anticipates announcing a new resource for Beatons Creek around the end of Q1 2019.

Novo Resources Corp. (NSRPF), closed Friday's trading session at $1.5609, up 1.36%, on 105,412 volume with 85 trades. The average volume for the last 3 months is 96,935 and the stock's 52-week low/high is $1.42/$5.01.

chart

iAnthus Capital Holdings, Inc. (ITHUF)

InvestorsHub, Stockhouse, MarketWatch, New Cannabis Ventures, GuruFocus, Daily Marijuana Observer, Morningstar, Barchart, OTC Markets, and Proactive Investors reported earlieron iAnthus Capital Holdings, Inc. (ITHUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

iAnthus Capital Holdings, Inc.isa provider of capital investment and management services to licensed cannabis cultivators, processors, and dispensaries across the U.S. The Company, by way of its 100 percent owned subsidiary, iAnthus Capital Management, LLC, delivers a complete solution for financing and managing these enterprises.iAnthussupportsa diverse portfolio of cannabis industry investments. OTCQX-listed,iAnthus Capital Holdings is headquartered in New York, New York.

iAnthus provides a unique combination of capital andpracticaloperating and management expertise. The Company creates agreements that establish valuable partnerships. It has developed strategic partnerships with best-in-class industry-sector leaders in dispensary operations, commercial-scale cannabis cultivation, regulatory law, and the science of cannabis product formulation and testing. Moreover, iAnthus continues to market its award-winning line of MPX-branded products.

At present, iAnthus has operations in 11 states, and operates 20 dispensaries. The Company is rapidly progressing its long-term plan to install more than half-a-million square feet of cultivation at its Lake Wales, Florida, campus. iAnthus' New York State operation is one of only ten licensed medical cannabis Registered Organizations in the State. In addition, the Company's Brooklyn location opened in late 2018. It is one of only three stores serving a city of 2.6 million.

iAnthus Capital Holdings has opened two dispensaries in Florida. This includes its flagship store in West Palm Beach. iAnthus has plans to quickly expand through 2019. It will be adding roughly one store a month. At the same time, it will be expanding its cultivation and processing operations.

In the State of Massachusetts, iAnthus is building a 41,000-square-foot facility. It will accommodate a fully integrated license, which includes cultivation, production and a dispensary on 12 acres in the Fall River area. This is in addition to the Company's 30,000-square-foot facility in Holliston. Furthermore, in Vermont, iAnthus has made major upgrades to its 6,000-square-foot cultivation and processing facility in Brandon. The Company has also started construction on a 49,700-square-foot medical cannabis cultivation and processing facility in Warwick, New York.

Recently, iAnthus Capital Holdings announced that it opened its second New York dispensary in the Dutchess County town of Wappingers Falls. This dispensary will operate as "Citiva Hudson Valley" under the iAnthus' "Citiva" New York dispensary brand. This retail location will initially offer greater than 30 locally-sourced, lab-tested products, including vape cartridges, tinctures, capsules, and powders, dispensed by highly-knowledgeable patient care representatives. 

                        

iAnthus Capital Holdings, Inc. (ITHUF), closed Friday's trading session at $4.87, up 4.64%, on 269,357 volume with 769 trades. The average volume for the last 3 months is 607,767 and the stock's 52-week low/high is $3.17/$7.27.

chart

MGX Minerals, Inc. (MGXMF)

Proactive Investors, Wall Street PR, InvestorsHub, Wallet Investor, Dividend Investor, Stockhouse, OTC Markets, MarketWatch, 4-Traders, Morningstar, Capital Equity Review, The Street, Stockwatch, Equities, StockInvest.us, The Streetwise Reports, Barchart, and Market Screener reported previously on MGX Minerals, Inc. (MGXMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MGX Minerals, Inc. is a diversified resource company with its corporate headquarters in Vancouver, British Columbia. It centers on the development of large-scale industrial mineral portfolios in specific commodities and jurisdictions that will fuel the new energy economy. MGX Minerals controls considerable interest in lithium, magnesium and silicon assets throughout North America. The Company lists on the OTC Markets Group's OTCQB.

MGX Minerals' strategy is to identify commodities and jurisdictions where large-scale development opportunities exist. Additionally, the Company's strategy is to build its asset portfolio via aggressive acquisition to quickly build and enhance long-term portfolio value. Furthermore, its strategy is to engage industry experts to lessen execution risk and quickly increase time to market.

The Company has regional control in most of the industrial mineral projects in the jurisdictions it operates. Pertaining to near-term potential, MGX Minerals concentrates on assets that offer streamlined development timelines and low initial capital expenditures (capex). It has developed a proprietary, low-energy design process (Rapid Recovery Process) that is patent-pending. The design of it is specifically for highly-mineralized brine associated with oilfields. The process quickly concentrates lithium and other minerals in brine.

MGX Minerals has completed pilot plant testing in South America on brine samples originating from numerous salars in Chile. The Company entered into a joint brine testing agreement with several South American mining companies. The parties are working to identify potential joint-venture (JV) locations that will utilize MGX Minerals' lithium extraction technology.

Recently, MGX Minerals and engineering partner PurLucid Treatment Solutions reported that a second deployment of an advanced wastewater treatment system is near completion and commissioning is anticipated soon. This system is capable of processing up to 10m3 per hour. The system will substantially decrease greenhouse gases through energy savings on steam generation. The technology provides superior treatment outcomes versus conventional technology that requires offsite trucking and high cost (because of toxicity) disposal. PurLucid Treatment Solutions' exclusively licensed and patented nanoflotation technology was designed purposely for oilfield environments.

MGX Minerals also recently reported that its collaborative research partnership with the University of British Columbia (UBC) completed a wide-ranging baseline assessment of metallurgical silicon originating from each of MGX's three silicon projects in southeastern British Columbia. The Company and UBC are working together to develop next-generation Li-ion batteries capable of quadrupling energy density from present 100 Wh/kg up to 400 Wh/kg for use in long-range electric vehicles and grid storage.

MGX Minerals, Inc. (MGXMF), closed Friday's trading session at $0.20, up 3.50%, on 86,361 volume with 26 trades. The average volume for the last 3 months is 143,604 and the stock's 52-week low/high is $0.159/$1.08.

chart

Aerpio Pharmaceuticals, Inc. (ARPO)

Market Chameleon, Hot Stock Cafe, High Rising Stocks, Street Insider, Stocktwits, 4-Traders, Barchart, Zacks, Business Wire, OTC Markets, Morningstar, OTC Stock Picks, Insider Tracking, and MarketWatch reported beforehand on Aerpio Pharmaceuticals, Inc. (ARPO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Aerpio Pharmaceuticals, Inc. focuses on first-in-class treatments for ocular diseases. The Company's lead compound is AKB‐9778. This is a small molecule activator of the Tie2 pathway. It is in clinical development for the treatment of non-proliferative diabetic retinopathy. A biopharmaceutical Company, Aerpio Pharmaceuticals has its corporate office in Cincinnati, Ohio. The Company lists on the NasdaqCM.

Currently, AKB-9778 is in a Phase 2b study(TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic Retinopathy (DR) is a complication of diabetes caused by damage to blood vessels in the retina. AKB-9778 is undergoing development as a subcutaneous injection.

Aerpio Pharmaceuticals' second program in development builds on its unique approach to targeting theTie2pathway.ARP-1536is a humanized monoclonal antibody. It works by binding the extracellular domain of VE-PTP, inhibiting its ability to interact with the Tie2 receptor. This prevents the inactivation of Tie2. In addition, it promotes vascular stability.

ARP-1536 is in pre-clinical development. Aerpio's plan is to develop ARP-1536 in combination with anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Furthermore, AKB-4924 is in Phase 1 clinical development. The Company's plan is to develop it as a once-daily, oral treatment for inflammatory bowel disease (IBD). AKB-4924 is an innovative small molecule inhibitor of prolyl-hydroxylase domain enzymes (PHDs).

In January, Aerpio Pharmaceuticals announced the completion of patient dosing in its TIME-2b study. This is the aforementioned Phase 2b clinical trial designed to assess the efficacy and safety of the Company's lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).

Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio Pharmaceuticals, said, "We are pleased to announce completion of patient dosing in our 48-week Phase 2b trial, TIME-2b. We now expect to announce top-line results in March 2019, earlier than our previous guidance of the second quarter of 2019."

Recently, Aerpio Pharmaceuticals announced that its Q4 and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019. Following the release, Aerpio will host a live conference call and webcast at 8:30 a.m. EST to discuss its financial results and provide a general business update.

Aerpio Pharmaceuticals, Inc. (ARPO), closed Friday's trading session at $1.04, up 0.96%, on 375,213 volume with 848 trades. The average volume for the last 3 months is 596,995 and the stock's 52-week low/high is $0.879/$4.95.

chart

Teranga Gold Corporation (TGCDF)

The Street, Stockhouse, OTC Markets, 4-Traders, Capital Equity Review, Simply Wall St, Street Insider, InvestorsHub, The Northern Miner, 24hgold, Canadian Insider, Junior Mining Network, GuruFocus, YCharts, Investcom, and MarketWatch reported beforehand on Teranga Gold Corporation (TGCDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Teranga Gold Corporation is a multi-jurisdictional West African gold company listed on the OTCQX. Its emphasis is on production and development and the exploration of more than 6,400 km2 of land located on prospective gold belts. The Company is advancing its Wahgnion Gold Project, with an earlier released positive Feasibility Study (FS), and conducting extensive exploration programs in Burkina Faso, Senegal and Côte d'Ivoire. Teranga Gold is based in Toronto, Ontario.

The Company has close to 4.0 million ounces of gold reserves from its combined Sabodala Gold operations and Wahgnion Gold Project. Since its initial public offering (IPO) in 2010, Teranga Gold has produced greater than 1.4 million ounces of gold from its operations in Senegal, which as of June 30, 2017, had a reserve base of 2.7 million ounces of gold.

Teranga Gold owns and operates the Sabodala Gold mine, which is the only gold mine and mill in Senegal, West Africa. This mine is roughly 650 km southeast of Dakar, the capital of Senegal. Sabodala has been in operation since 2009. The Sabodala Mining Concession and the surrounding exploration permits are positioned within the highly prospective Kedougou-Kenieba Inlier that forms part of the Paleoproterozoic age Birimian Terrane of the West African Craton.

In October of 2016, the Banfora Gold Project was acquired as part of Teranga Gold's acquisition of Gryphon Minerals. The fully permitted, high-grade, open pit Banfora Gold Project is in the southwest of Burkina Faso, West Africa. It is in a major gold producing district host to a number of first-rate gold deposits. Teranga Gold owns 90 percent of the Project. The Burkina Faso government owns the remaining 10 percent.

Teranga Gold has acquired the remaining 49 percent interest in the Golden Hill and Gourma projects from Boss Resources Limited. Teranga previously had the right to increase its 51 percent stake and earn up to an 80 percent interest in each project upon delivery of an FS on either project and the payment of AUD2.5 million. With the transaction, Teranga Gold owns a 100 percent interest in each of the Golden Hill and Gourma projects in Burkina Faso, West Africa.

Recently, Teranga Gold announced an initial mineral resource estimate for its Golden Hill advanced exploration project, situated within the central part of the highly mineralized Houndé Greenstone Belt in southwest Burkina Faso, West Africa. Golden Hill resource estimate highlights include Indicated mineral resources of 6.40Mt averaging 2.02 g/t gold for 415,000 ounces. Highlights also include Inferred mineral resources of 11.95Mt averaging 1.68 g/t gold for 644,000 ounces. There is excellent along trend and to-depth continuity of gold mineralization at all prospects drilled.

Additionally, Teranga Gold recently reported its operating and financial results for the three and twelve months ended December 31, 2018. The Company also provided an update on the development of its second mine, Wahgnion Gold Operations. Operating highlights include record full-year gold production of 245,230 ounces, surpassing the high end of the Company's increased 2018 production guidance range of 235,000-240,000 ounces.

Wahgnion Gold Operations achieved significant construction project milestones in 2018. It is on track for first gold pour and ramp up to nameplate production in Q4 2019. It increased open-pit mineral reserves by approximately 40 percent to 1.6 million ounces. Moreover, Wahgnion increased mine life to 13 years and improved first five years' production and cost profile

Teranga Gold Corporation (TGCDF), closed Friday's trading session at $2.30, up 1.39%, on 12,110 volume with 24 trades. The average volume for the last 3 months is 28,327 and the stock's 52-week low/high is $2.23/$4.32.

chart

BioCorRx, Inc. (BICX)

Stockhouse, InvestorsHub, Equity Clock, Equity Observer, TMXmoney, OTPicks, Massive Stock Profits, Stockwatch, The Street, Barchart, Buyins.net, PrePump Stocks, Penny Picks, Damn Good Penny Picks, Penny Stock Newsletter, SmallCapVoice, Value Penny Stocks, and PennyStocks24 reported beforehand on BioCorRx, Inc. (BICX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

BioCorRx, Inc. is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. It provides an innovative approach to the treatment of substance abuse addiction and has its BioCorRx® Recovery Program. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program. The Company's emphasis is on improving the quality of life for recovering addicts. BioCorRx Pharmaceuticals is the Company's research and development (R&D) subsidiary. BioCorRx has its corporate headquarters in Anaheim, California.

The BioCorRx® Recovery Program consists of two principal components. The first component comprises an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist, which can considerably reduce physical cravings for alcohol and opioids.

The second component is a one-on-one proprietary counseling program. It is mainly tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatments. BioCorRx has also expanded the support structure to include 12 months of a peer-support system using trained recovery specialists. Moreover, it is developing a patent pending injectable form of naltrexone.

BioCorRx® has submitted a grant application to the National Institutes of Health (NIH) to fund the development and study plans for BICX102. This is the Company's single administration, multi-month sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.

At present, the BioCorRx Pharmaceuticals subsidiary is developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd.  BICX101 is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. BioCorRx's plan is to seek Food and Drug Administration (FDA) approval for BICX101 and/or its naltrexone implant product(s).

Recently, BioCorRx announced that it was awarded a 2-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925 for the development of BICX102. BioCorRx is seeking FDA approval for BICX102.

BioCorRx also recently announced the formation of its Scientific Advisory Board (SAB) with three key appointments. These appointments are David R. Gastfriend, M.D., DFASAM, Evgeny Krupitsky M.D., Ph.D., D.M.Sc., and George E. Woody, M.D. The SAB will work closely with the Company's management team as it continues to advance its lead product candidate, BICX102.

BioCorRx, Inc. (BICX), closed Friday's trading session at $5.25, up 1.94%, on 268 volume with 5 trades. The average volume for the last 3 months is 2,703 and the stock's 52-week low/high is $3.50/$10.00.

chart

Emergent Capital, Inc. (EMGC)

OTC Markets, MarketWatch, Simply Wall St, The Street, last10k, Stockhouse, Equity Clock, Zacks, Seeking Alpha, Barchart, Street Insider, Trading View, GuruFocus, Stockopedia, YCharts, 4-Traders, Market Screener, Financial Content, and InvestorsHub reported earlier on Emergent Capital, Inc. (EMGC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Emergent Capital, Inc. is a specialty finance company listed on the OTC Markets' OTCQX. It invests in life settlements and is a worldwide leader in the life settlements industry. The Company has decades of experience creating value by way of the secondary and tertiary markets for life insurance policies. Emergent Capital established in 2006 as Imperial Holdings, LLC. The Company has been publicly traded since 2011. Emergent Capital is headquartered in Boca Raton, Florida. In 2015, shareholders voted to change the Company's name to Emergent Capital, Inc.

Concerning Life settlements; they are an alternative asset class that can provide high uncorrelated returns. For investor consideration, life settlements have limited correlation to the stock market or the larger economic market. They can serve as a hedge against the volatility of more market-dependent investments. In addition, life settlements represent a compelling and diversified investment opportunity to include longevity risk in a portfolio.

Emergent Capital has access to a wide-ranging and proven network of life settlement brokers and third-party providers from whom it sources attractive and value-added policies. Essentially, Emergent Capital purchases individual policies and portfolios of life insurance policies. It manages these assets based on comprehensive actuarial and market data. Furthermore, an Emergent Capital subsidiary can act as a life settlement provider in over 30 States where it is able to pursue manifold opportunities within the life settlement space.

Emergent Capital's goal is to produce a consistent flow of investment opportunities covering all facets of the life settlements market. These range from lending to outright purchases of portfolios, to tertiary trades, and also individual secondary market purchases.

This past November, Emergent Capital announced its financial results for the three month and nine month periods ended September 30, 2018. Q3 2018 financial highlights include Total Income from Continuing Operations of $29.7 million for the three month period ended September 30, 2018 versus $24.5 million for the same period in 2017. Income was impacted by a $20.1 million gain on the maturity of six policies during the quarter versus an $11.6 million gain on maturity of three policies for the same period the year prior.

Total Income from Continuing Operations was $40.9 million for the nine month period ended September 30, 2018 versus $53.5 million for the same period in 2017. Income was impacted by a $48.1 million gain on the maturity of 18 policies during the quarter versus a $30.6 million gain on maturity of 10 policies for the same period the year prior.

Emergent Capital, Inc. (EMGC), closed Friday's trading session at $0.10, up 1.01%, on 1,110 volume with 1 trade. The average volume for the last 3 months is 67,167 and the stock's 52-week low/high is $0.0302/$0.40.

chart

Innovation Pharmaceuticals, Inc. (IPIX)

Streetwise Reports, Tip Ranks, Insider Financial, Stockopedia, InvestorsHub, Emerging Growth, Stockdigest Report, MarketWatch, Real Investment Advice, Simply Wall St, Stockhouse, The OTC Reporter, Wallet Investor, Investors Hangout, and Barchart reported earlier on Innovation Pharmaceuticals, Inc. (IPIX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Innovation Pharmaceuticals, Inc. is an OTCQB-listed clinical stage biopharmaceutical company. It is developing unique therapies in manifold diseases. Its belief is that it has a premier portfolio of first-in-class lead drug candidates. The Company is presently advancing them toward market approval, while seeking strategic partnerships. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts. Innovation is establishing a wholly-owned European subsidiary for the purpose of the development of its drug candidates globally.

The Company's anti-cancer drug is Kevetrin. It successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Innovation Pharmaceuticals commenced a Phase 2 study in Ovarian Cancer.

Innovation has its Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of OM in patients with head and neck cancer. Brilacidin - a defensin mimetic compound - has shown in an animal model to reduce the occurrence of severe ulcerative Oral Mucositis (OM) by greater than 94 percent versus placebo.

Brilacidin completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the Food and Drug Administration (FDA)-approved seven-day dosing regimen of daptomycin.

The Company's Psoriasis drug candidate is Prurisol. It completed a Phase 2 trial and Innovation launched a Phase 2b study. Prurisol is a small molecule. It acts via immune modulation and PRINS reduction.

This past December, Innovation Pharmaceuticals announced that the Company and the U.S. Food and Drug Administration (FDA) completed an End-of-Phase 2 meeting regarding the continuing development of Brilacidin oral rinse to reduce the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation. Brilacidin oral rinse is undergoing development under FDA Fast Track designation for Oral Mucositis (OM).

Both parties agreed to an acceptable Brilacidin Phase 3 development pathway. This includes studying Brilacidin oral rinse effects on SOM when cisplatin is administered in higher concentrations (80-100 mg/m2) every 21 days, and at lower concentrations (30-40 mg/m2) administered weekly as part of the chemoradiation regimen.

Recently, Innovation Pharmaceuticals announced plans to initiate this year a clinical trial of Brilacidin as an oral dosage form. Building upon the successful Phase 2 Proof-of-Concept (PoC) clinical trial for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), the goal of the program is to develop treatment for the more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn's Disease. Innovation Pharmaceuticals also recently announced that the Companies Registration Office Ireland provided notification that Innovation's subsidiary, IPIX Pharma Limited, is registered under the Companies Act 2014, effective February 15, 2019. As Innovation will now be engaging the European Medicines Agency (EMA) to advance its clinical pipeline, the benefits of the subsidiary to the Company will be immediate.

Innovation Pharmaceuticals, Inc. (IPIX), closed Friday's trading session at $0.171, up 9.62%, on 403,204 volume with 66 trades. The average volume for the last 3 months is 411,377 and the stock's 52-week low/high is $0.07/$0.695.

chart

Pura Naturals, Inc. (PNAT)

OTC Markets, Whale Wisdom, YCharts, Spotlight Growth, Stockwatch, Clay Trader, Insider Financial, Marketwired, Tip Ranks, Dividend Investor, and MarketWatch reported previously on Pura Naturals, Inc. (PNAT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Pura Naturals, Inc. is working to deliver a purer clean via its unique BeBetter Foam®. The Company is the manufacturer of innovative foam cleaning products for the home. It has its proprietary foam technology that absorbs grease and grime like a magnet. It does so without harsh chemicals and harboring of bacteria found within traditional household cleaning products and sponges. Pura Naturals is headquartered in Lake Forest, California.

Pura Naturals centers on plant-based products made from renewable resources with no petroleum by-products. Its product portfolio includes Health & Beauty products, including facial pads, exfoliating soap-infused body bars, soap-infused sponges, and soap-infused gentle cleansing pads for babies.

Kitchen & Household products include sponges, soap-infused sponges, non-scratch scrubbers, and non-scratch scrubbers (soap-infused). Pura Naturals' household cleaning products deliver a unique soap infusion. The pioneering foam absorbs grease while repelling water and inhibiting bacteria growth and odors.

In addition, the Company has its Pura Naturals Marine. The specific design of its marine foam is to handle petroleum base contaminations. It is approved for use by the Environmental Protection Agency (EPA). Marine products include all-purpose sorbent Spill Pads, bilge sorbent Bilge Booms, Spill Bibs (fuel spill prevention), soap-infused personal cleaning bars, and soap-infused galley sponges.

The Pura Marine division concentrates on developing solutions utilizing AirTech Foam technologies and allied products directed towards oil spill prevention and remediation in waterways. This division is pursuing business in the trucking and oil sectors. Pura Naturals also has its all-natural cleaning solution, Pura Pro Bio-Degreaser. This product is a strong citrus based, multi-use cleaner. In addition, the Company has its line of health and beauty products. These products will be infused with Cannabidiol (CBD) derived from hemp and hemp seed oils.

Pura Naturals has its Grease Beast products and this week the Company announced the increased synergy the Grease Beast products are experiencing. Recently, Pura Naturals attended the Orgill Dealer Market Show in Orlando, Florida, February 21 to the 23, with further very encouraging results.

Mr. Robert Doherty, Chief Executive Officer of Pura Naturals, stated, "It was a great show for the Company. There continues to be tremendous reception for the Grease Beast product line. It was our best show ever for the brand. We received the most orders during a show to date.  We are now working directly with top Orgill representatives."

Pura Naturals, Inc. (PNAT), closed Friday's trading session at $0.0035, up 20.69%, on 1,227,009 volume with 14 trades. The average volume for the last 3 months is 3,583,659 and the stock's 52-week low/high is $0.0015/$0.033.

chart

BioHiTech Global, Inc. (BHTG)

Stock Twits, OTC Markets, Market Exclusive, Dividend Investor, Real Investment Advice, Stockopedia, Barchart, Market Screener, Zacks, last10k, Insider Financial, Stockaholics, YCharts, Talk Traders, Stockhouse, MarketWatch, Wallet Investor, Market News Updates, InvestorsHub, Street Insider, 4-Traders, and Trading View reported earlier on BioHiTech Global, Inc. (BHTG), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

BioHiTech Global, Inc. is a green technology business that provides unique data-driven solutions for food waste disposal. The Company develops and deploys innovative and disruptive waste management technologies. BioHiTech Global is a leader in zero waste solutions for businesses and municipalities of all sizes. NasdaqCM-listed, BioHiTech Global has its corporate headquarters in Chestnut Ridge, New York.

In 2016, BioHiTech Global expanded its waste stream product offering with the launch of Entsorga North America. The Entsorga North America undertaking expands the Company's product offering towards providing disruptive, clean technology solutions that advance the worldwide movement towards sustainability and zero waste initiatives.

BioHiTech Global provides waste management solutions to an international customer base covering a complete set of technology-based disposal options, which can have a significant effect on waste generation. This is while providing a true zero landfill environment.

BioHiTech Global has launched its BioHiTech Alto™. This is a next generation interactive industrial communication technology. BioHiTech Alto™ enables users to communicate intelligently with industrial equipment in real-time. BioHiTech Alto is a vital new element of the Company's total food waste solution that uses data and analytics to help drive smarter business decisions. Furthermore, BioHiTech Global launched BioHiTech Cirrus. This is a mobile application for complete insight into the waste stream.

BioHiTech Global announced this past December that its Entsorga West Virginia, LLC (EWV) subsidiary completed an $8 million tax-exempt bond financing to finalize construction and commence operations at the nation's first HEBioT™ renewable resource recovery facility in Martinsburg, West Virginia. BioHiTech Global earlier entered into a definitive agreement to become the largest owner of EWV.

BioHiTech Global's plan is to build a series of facilities using the patented HEBioT process in the U.S. in the coming years. A second site is presently under development in Rensselaer, New York, with other potential locations in early stage planning.

In December 2018, BioHiTech Global announced that a portfolio company of Kinderhook Industries, a private investment firm that manages more than $2.0 billion of committed capital, contributed $3.5 million in cash and assets valued at roughly $2 million in exchange for a 40 percent stake in a newly created BioHiTech consolidated subsidiary. The New Subsidiary currently owns a 78 percent equity interest in the nation's first HEBioT™ facility in Martinsburg, West Virginia and certain assets related to BioHiTech's Rensselear HEBioT development project. This New Subsidiary will serve as the stage for BioHiTech's planned HEBioT facility rollout in the U.S.

BioHiTech Global, Inc. (BHTG), closed Friday's trading session at $2.4721, up 4.31%, on 4,535 volume with 50 trades. The average volume for the last 3 months is 28,129 and the stock's 52-week low/high is $1.60/$5.76.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Leading California edibles manufacturer Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) is making moves to dominate the branded cannabis industry through its continued focus on premium products executed with precision and made available to consumers everywhere.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $4.019, up 10.98%, on 146,028 volume with 262 trades. The average volume for the last 3 months is 84,765 and the stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Dynamic plant-based food and beverage company Canopy Rivers (TSX.V: RIV) (OTC: CNPOF) today announced that its portfolio company TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) has been issued a Good Manufacturing Practice ("GMP") certificate in accordance with the rules governing medicinal products in the European Union ("EU") for its Mississauga, Ontario, Canada facility. To view the full press release, visit: http://nnw.fm/2ujOT.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (RIV), closed the day's trading session at $3.89, up 2.37%, on 139,859 volume with 487 trades. The average volume for the last 3 months is 598,770 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to confirm that the Hamilton City Council and the Company have finalized and signed a settlement offer, and that the Local Planning Appeal Tribunal approved the settlement at a meeting on May 2, 2019. The facilities in Ancaster, Ontario will be capable of growing 17,500 kgs of premium certified organic cannabis annually.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $3.24, up 2.93%, on 508,307 volume with 877 trades. The average volume for the last 3 months is 1,274,672 and the stock's 52-week low/high is $1.61/$7.89.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) this morning announced its participation at select capital markets and cannabis conferences that are scheduled throughout the month of May. To view the full press release, visit: http://nnw.fm/nCU8A. Also today, the company was highlighted is Canada's only large-scale premium cannabis producer. The company formed its wholly owned 7ACRES subsidiary as the first licensed producer ("LP") centered on growing high-quality cannabis in high quantities.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.45, up 1.40%, on 221,647 volume with 419 trades. The average volume for the last 3 months is 651,588 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings Inc. (OTCQB: NGTF), an innovative consumer goods and brand development company, is pioneering the category of "sleep-friendly" nutrition with the national roll-out of its award-winning Nightfood ice cream. Leading marketing intelligence agency Mintel noted that nighttime-specific food and beverages represent one of the "most compelling and category changing" trends for the coming years (http://nnw.fm/YeOQ7). Nightfood aims to revolutionize the way Americans snack at night.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.6594, up 0.70%, on 87,482 volume with 59 trades. The average volume for the last 3 months is 560,618 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade Inc. (OTCQB: SGMD) was featured today in the 420 with CNW by CannabisNewsWire. Moosehead Breweries Ltd, one of the largest breweries in Canada, has announced that it plans to form a joint venture with Sproutly Canada, Inc. in order to make cannabis-infused drinks. The drinks will be introduced on the Canadian market by the end of this year.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.039, up 0.26%, on 561,895 volume with 56 trades. The average volume for the last 3 months is 1,265,567 and the stock's 52-week low/high is $0.035/$0.198.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

An integrated pharmaceutical services company, Trxade Group Inc. (OTCQB: TRXD) offers an S2P (Supplier to Pharmacy) market platform. The platform helps independent pharmacies operating nationwide to identify the best available supplier prices for prescription drugs. Trxade is the largest online pharmaceutical marketplace platform in the United States. Per corporate data, the platform has been shown to reduce a pharmacy's total yearly purchase costs by 7-10 percent (http://nnw.fm/Cdxj4).

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed the day's trading session at $0.44, even for the day. The average volume for the last 3 months is 2,553 and the stock's 52-week low/high is $0.23/$1.00.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG), formerly Sharing Services Inc., has been rapidly growing over the past several months, adding more than 10,000 independent sales representatives and positioning itself as one of the fastest-growing direct-selling companies in the world. To view the full article, visit: http://nnw.fm/1Ai8p.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed the day's trading session at $0.22585, even for the day, on 150 volume. The average volume for the last 3 months is 47,813 and the stock's 52-week low/high is $0.17/$0.449.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

Transcanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") is pleased to announce today the execution of a non-binding Letter Of Intent dated April 30th, 2019 to acquire the branding asset package, Biovelle, a hemp based CBD coconut oil from an arm's length third party.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $7.12, off by 3.78%, on 24,341 volume with 73 trades. The average volume for the last 3 months is 167,027 and the stock's 52-week low/high is $0.77/$7.79.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada Inc. (OTCQB: SRUTF) (CSE: SPR) announces the availability of a CannabisNewsAudio Broadcast titled, "Next Stage Cannabis Stocks in the Spotlight." To hear the CannabisNewsAudio version, visit: http://cnw.fm/y9shU. To read the full editorial, visit: http://cnw.fm/Sf6v5.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed the day's trading session at $0.57108, off by 0.70%, on 591,830 volume with 317 trades. The average volume for the last 3 months is 720,177 and the stock's 52-week low/high is $0.189/$1.875.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF), a fully integrated oil and gas company, announced on April 16, 2019, that it is executing a definitive agreement for the acquisition of an additional 50 percent of the operating rights and interests relating to oil sands in the state of Utah, under U.S. federal oil and gas leases. Also today, NetworkNewsWire released a report on the company detailing how PQEFF recently reported consistent production of over 500 barrels per day ("bpd"). To view the full article, visit: http://nnw.fm/0myT2 .

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PHVAF), closed the day's trading session at $0.256, off by 6.23%, on 111,651 volume with 55 trades. The average volume for the last 3 months is 147,132 and the stock's 52-week low/high is $0.242/$1.43.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.83, up 4.57%, on 1,961 volume with 16 trades. The average volume for the last 3 months is 47,488 and the stock's 52-week low/high is $0.95/$18.44.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.56, up 12.02%, on 87,743 volume with 41 trades. The average volume for the last 3 months is 33,669 and the stock's 52-week low/high is $0.375/$26.45.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.4821, up 8.51%, on 138,526 volume with 84 trades. The average volume for the last 3 months is 457,114 and the stock's 52-week low/high is $0.417/$0.791.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.